Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study

被引：0
|
作者：
Mikio Sugimoto
Takuma Kato
Yoichiro Tohi
Yosuke Shimizu
Ryuji Matsumoto
Takahiro Inoue
Yutaka Takezawa
Kimihiko Masui
Hiroshi Sasaki
Hiromi Hirama
Shiro Saito
Shin Egawa
Toshiyuki Kamoto
Satoshi Teramukai
Shinsuke Kojima
Takashi Kikuchi
Yoshiyuki Kakehi
机构：
[1] Kagawa University,Department of Urology, Faculty of Medicine
[2] Kobe City Nishi-Kobe Medical Center,Department of Urology
[3] Hokkaido University Graduate School of Medicine,Department of Urology
[4] Kyoto University,Department of Urology, Graduate School of Medicine
[5] Isesaki Municipal Hospital,Department of Urology
[6] Otsu City Hospital,Department of Urology
[7] Jikei University School of Medicine,Department of Urology
[8] National Hospital Organization Tokyo Medical Center,Department of Urology
[9] University of Miyazaki,Department of Urology, Faculty of Medicine
[10] Kyoto Prefectural University of Medicine,Department of Biostatistics
[11] Foundation for Biomedical Research and Innovation at Kobe Translational Research Center for Medical Innovation,undefined
来源：
BMC Urology | / 22卷
关键词：
Combined androgen blockade; Enzalutamide; Non-metastatic castration-resistant prostate cancer; Progression-free survival; Radical treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer
    Shore, Neal
    Carles, Joan
    McDermott, Ray
    Agarwal, Neeraj
    Tombal, Bertrand
    FRONTIERS IN MEDICINE, 2024, 11
  • [42] Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States
    Arif Hussain
    Shan Jiang
    Della Varghese
    Sreevalsa Appukkuttan
    Nehemiah Kebede
    Kajan Gnanasakthy
    Cynthia Macahilig
    Reg Waldeck
    Shelby Corman
    BMC Cancer, 22
  • [43] Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States
    Hussain, Arif
    Jiang, Shan
    Varghese, Della
    Appukkuttan, Sreevalsa
    Kebede, Nehemiah
    Gnanasakthy, Kajan
    Macahilig, Cynthia
    Waldeck, Reg
    Corman, Shelby
    BMC CANCER, 2022, 22 (01)
  • [44] Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer
    Chung, Doo Yong
    Ha, Jee Soo
    Cho, Kang Su
    BIOMEDICINES, 2021, 9 (06)
  • [45] First-Line Treatment After the Failure of Androgen Deprivation Therapy for Non-Metastatic, Castration-Resistant Prostate Cancer Men
    Zhu, Yuhong
    Yang, Gaojie
    Ding, Yangyang
    Wu, Lifen
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2022, 18 (04) : 714 - 720
  • [46] ?Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil?
    Jardim, Denis L.
    Silva, Adriano Goncalves e
    Pompeo, Alexandre Saad Fere Lima
    Sarkis, Alvaro Sadek
    Cardoso, Ana Paula Garcia
    Sasse, Andre Deeke
    Fay, Andre Poisl
    Soares, Andrey
    Pompeo, Antonio Carlos Lima
    Carneiro, Arie
    Kann, Ariel Galapo
    Fogassa, Camilla
    De Freitas Jr, Celso Heitor
    Chade, Daher Cezar
    Herchenhorn, Daniel
    De Almeida, Daniel Vargas Pivato
    Da Rosa, Diogo Augusto Rodrigues
    Wiermann, Evanius Garcia
    Schutz, Fabio Augusto Barros
    Kater, Fabio Roberto
    De Moura, Fernando
    Korkes, Fernando
    Meyer, Fernando
    De Oliveira, Fernando Nunes Galvao
    Sabino, Fernando
    Almeida, Gilberto Laurino
    Avanco, Guilherme
    Guimaraes, Gustavo Cardoso
    Lemos, Gustavo Caserta
    Carvalhal, Gustavo Franco
    Kim, Hanna
    Morbeck, Igor Protzner
    Campagnari, Joao Carlos
    Rinck Jr, Jose Augusto
    Da Ponte, Jose Ricardo Tuma
    Da Trindade, Karine Martins
    Atem, Leonardo
    Borges, Leonardo
    Nogueira, Lucas Mendes
    Batista, Lucas Teixeira e Aguiar
    Maia, Manuel Caitano
    Sadi, Marcus Vinicius
    Rocha, Maria Alzira Almeida
    Luz, Murilo De Almeida
    Smaletz, Oren
    Lages, Paulo Sergio Moraes
    Matuda, Raquel Midori Koga
    Dos Reis, Rodolfo Borges
    Indio, Rodrigo Frota
    Fernandes, Roni De Carvalho
    CLINICAL GENITOURINARY CANCER, 2023, 21 (02) : e58 - e69
  • [47] Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy- naive Metastatic Castration-resistant Prostate Cancer Patients
    Azad, Arun A.
    Eigl, Bernhard J.
    Murray, R. Nevin
    Kollmannsberger, Christian
    Chi, Kim N.
    EUROPEAN UROLOGY, 2015, 67 (01) : 23 - 29
  • [48] An interim analysis of non-interventional study of the epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia
    Alekseev, B. Ya
    Nyushko, K. M.
    Gafanov, R. A.
    Kirichek, A. A.
    Anzhiganova, Yu, V
    Kopyltsov, E., I
    Sundui, Yu Yu
    Matveev, V. B.
    ONKOUROLOGIYA, 2020, 16 (03): : 90 - 101
  • [49] Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice
    Rosinha, Alina
    Rabaca, Carlos
    Calais, Fernando
    Pinto, Joao Moreira
    Barreira, Joao Vasco
    Fernandes, Ricardo
    Ramos, Rodrigo
    Fialho, Ana Cristina
    dos Reis, Jose Palma
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [50] Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study
    Taro Iguchi
    Satoshi Tamada
    Minoru Kato
    Sayaka Yasuda
    Taiyo Otoshi
    Kosuke Hamada
    Takeshi Yamasaki
    Tatsuya Nakatani
    International Journal of Clinical Oncology, 2019, 24 : 848 - 856
12345